Issued: Tuesday 07 February 2012, London UK GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders 2011 underlying sales +4% (reported -3%) EPS before major restructuring* 114.1p Total …
Issued: Monday 30 January 2012, London, UK GlaxoSmithKline (GSK) today announced it has joined other global pharmaceutical companies and leading organisations including the World Health Organization (WHO), the Bill & Melinda Gates Foundation, the UK …
Issued: Friday 27 January 2012, London, UK GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr …
Issued: Wednesday 11 January 2012, London, UK GlaxoSmithKline respectfully disagrees with the recent court ruling in favour of ANMAT (the Argentinean National Administration of Medicines, Food and Medical Technology) on the fine issued to GSK regarding …
Issued: Monday 09 January 2012, London UK & South San Francisco, CA, USA GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III registration programme for the once-daily investigational …
Issued: Tuesday 20 December 2011, London UK Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m). Process continues for divesting brands outside these markets and global rights for alli In February …
Issued: Friday 16 December 2011, London UK GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world‟s poorest countries from pneumococcal disease. Pneumococcal disease can …
Issued: Thursday 15 December 2011, London UK & Philadelphia US - Study to enrol over 800 adult patients with SLE - Will evaluate once-weekly subcutaneous injections of an investigational formulation of belimumab plus standard of care vs. placebo plus …
Issued: Thursday 08 December 2011, London, UK - Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive breast cancer. Results from …
Issued: Wednesday 07 December 2011, London UK GSK and Help for Heroes today announced a new partnership to help support injured British armed forces personnel successfully transition back into civilian life. The partnership will focus on the creation of …
Issued: Monday 05 December 2011, London UK "The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investment. The actions on research and …
Issued: Thursday 01 December 2011, Philadelphia, PA GlaxoSmithKline [NYSE:GSK] today submitted additional information to the U.S. Food and Drug Administration (FDA) in support of the Biologics License Application (BLA) for the candidate …
Issued: Thursday 17 November 2011, London UK GlaxoSmithKline today welcomed the decision of the GAVI Board to provide funding to facilitate the provision of cervical cancer immunisation programmes and rubella vaccination, across the world’s poorest …
Issued: Thursday 17 November 2011, London UK GlaxoSmithKline (GSK) today welcomes the European Commission’s commitment to promote collaborative research efforts to develop new antibiotics against the growing threat from resistant bacteria. Within …
Issued: Wednesday 16 November 2011, London UK Head-to-head study primary end point did not meet non-inferiority, but results support progression towards registration GlaxoSmithKline (GSK) today announced that topline results have been received from the …
Issued: Wednesday 09 November 2011, London UK An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix ® , provided protection against advanced precancerous lesions (CIN3+), above that …
Issued: Monday 07 November 2011, London UK Full results from ENABLE 1 and initial data from ENABLE 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases Findings from the ENABLE clinical trials, which …
Issued: Monday 07 November 2011, London UK Full results from ENABLE 1 and initial data from ENABLE 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases Findings from the ENABLE clinical trials, which …
Issued: Thursday 03 November 2011, London, UK - $3 billion settlement covered by existing legal provisions - Fundamental changes to US compliance, marketing and selling procedures implemented in recent years GlaxoSmithKline plc (GSK) today …
Issued: Wednesday 26 October 2011, London, UK - EPS 28.5p +1% before major restructuring* - Dividend +6% to 17p - 2011 share buyback expectations increased to up to £2.3 billion Full details of GSK's results for the third quarter of 2011 can be …
04 days 23:55:33
